Trends and Market Analyses
46 Healthcare Metrics to Boost Profitability: Charting 2012 Trends, a graphic compendium of performance benchmarks in key areas of healthcare activity and growth, makes it easy for the healthcare C-suite to stay current, distilling the latest trends into a series of easy-to-digest charts and tables.
The German pharmaceutical market still looks inviting to drug manufacturers. Germany has one of the highest levels of health care spending in the world and has the largest pharmaceutical market in Europe. (Source: United BioSource Corp. “Evidence Matters” Newsletter, Oct 2010)
The State Snapshots provide State-specific health care quality information, including strengths, weaknesses, and opportunities for improvement. The goal is to help State officials and their public- and private-sector partners better understand health care quality and disparities in their State.
Discussion of emerging markets in India, China, and elsewhere. (Source: Gale, Cengage Learning, Business Wire, 2008)
This survey features responses captured over the course of seven business days from 48 Pan Asia-Pacific physicians in the GLG Healthcare CouncilsSM, representing cardiologists, hepatologists and diabetologists. The physician populations represented opinions from the three distinct reimbursement market types in the region: reimbursed markets, semi-reimbursed markets and self-pay markets. Respondents were asked about their prescribing preferences and hospital/formulary influences when considering foreign original branded therapies compared with local generic therapies.
The Atlas is published alongside the NHS Outcomes Framework to act as a catalyst for driving improvements in quality, outcome and value measurement throughout the NHS by encouraging a change in culture and behavior, including a renewed focus on tackling inequalities in outcomes.
This article summarizes findings of a report funded by The Commonwealth Fund Commission on a High Performance Health System, including 15 federal policy options and their potential for lowering health spending are examined. (Source: Brian Ahier, Health IT & Healthcare Reform, Nov 21, 2009)
Paid report including best practices from experts based on their experiences.
Canada ranks 10th among the 16 comparator countries in overall health outcomes and earns a "B" grade. The United States is the worst performer in the ranking and gets a "D" grade. (Source: Conference Board of Canada, Sept. 28, 2009)
Article provides a comparative look at countries that have implemented the Bismarck model of health care, which emphasizes a mixture of private and public administration to deliver services. Countries compared include US, France, Canada, UK, Taiwan, Germany, and Japan.
Fears of a PBM "pricing war" at the start of the 2011 contract season may have been exaggerated, as some reports indicate PBMs are lowering their prices at a slower pace than last year, while others suggest pricing is more aggressive (Source: AIS's Health Business Daily).
The Consumer-Directed Health Market: Implications of New Benefit Designs by The Zitter Group
Consumer Reports opinion poll found that only 4% of respondents had discussed drug price with their physician at point of prescribing; 66% "blindsided" by costs once they reached the pharmacy.
Determining European KOL Compensation: Fair-Market Value Benchmarks is a one-of-a-kind study backed by more than two dozen pharmaceutical, biotechnology, medical device, and CRO companies’ and third-party provider benchmark data. The study is dedicated to helping companies understand the unique differences in key opinion leader (KOL) compensation that exist in Europe.
This includes HTA, CEA, and discussion of barriers for Asia as a whole, Thailand, Taiwan, Uganda, Latin America and Caribbean, and low- and middle-income countries. (Source: Pharmaeconomics, Nov. 1. 2009)
It is very difficult to get good data on this in the pharma industry. In a recent survey, Cegedim Dendrite mentioned that less than 0.1% of the S&M spend was devoted to digital in 2009 in Europe; in a recent US survey by the same company, the number was estimated to be close to 10% for some of the leading companies.
ISPOR Connections discusses perspectives on the use and value of health economics from a governmental perspective from the UK, Germany, Sweden, Spain, The Netherlands. (Source: Mittendorf, ISPOR Connections, Nov/Dec. 2009, p.15)
Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates that promotion may adversely influence prescribing, physicians hold a wide range of views about pharmaceutical promotion.
The Netherlands has the best healthcare system in Europe, according to the annual Euro Health Consumer Index. (Source: Sarah Bruce, eHealthEurope, Oct 2009)
A new report (Economic Policy Reforms: Going for Growth 2011) finds that the U.S. spends far more on health care than any of the other 29 OECD nations, and gets less health for its money. Annual public and private health-care spending in the U.S. stands at $7,538 per person, 2.41 times the OECD average and 51% more than the second-biggest spender, Norway. Meanwhile, average U.S. life expectancy is 77.9 years, less than the OECD average of 79.4.(Source: OECD)
The results of the fourth annual “Emerging Trends Driving Changes in Pharmacy Benefits” survey sponsored by the Foundation for Managed Care Pharmacy (FMCP) have been released. The survey is made possible through the generous support of Merck & Company. The HSM Group conducted the survey and analysis. Concerns about the management of specialty pharmacy continued to eclipse other issues in this year’s survey, both in terms of judging clinical evidence and cost management.
Create and implement on your behalf employer based brand strategies that enhance product sales by increasing brand utilization in the employer workplace through ROI incentive based behavior change intervention initiatives.
Most big employers plan to shift a larger share of health-care costs to their workers next year, according to a survey released Thursday.
Many say they may charge more to cover spouses, tighten eligibility standards for their health plans and dispense financial rewards or penalties based on the results of certain lab tests. At some companies, overweight employees could be excluded from the most desirable plans. (Source: The Washington Post, March 12, 2010)
The FastStats site provides quick access to statistics on topics of public health importance and is organized alphabetically. Links are provided to publications that include the statistics presented, to sources of more data, and to related web pages.
Gateway to statistics from over 100 agencies. Sort by health and get links to AHRQ, CDC, CMS, etc. etc.
Describe the results from an AFPE survey on organizational structures and educational components of the pharmacoeconomics and outcomes research (PE/OR) fellowship programs in the United States.
According to the FDA, 7 in 10 Rxs filled in the U.S. today are for generic drugs. IMS Institute for Healthcare Informatics recently released a report that found spending on brand-name medications declined 0.7% in 2010, whereas spending on generics, both branded and unbranded, rose 4.5% and 21.7% respectively.
A clinical-trial strategy begun three years ago by GlaxoSmithKline Plc may be a model for other drugmakers as the U.S. health-care overhaul pushes insurers to look more closely at how much they spend on new drugs.
Paid Report (but a sample is downloadable for free): Global Biotech Market Analysis and Forecasts, 2008-2023, from Visiongain.com. This report covers both the top ten therapy classes as well as the top ten leading pharmaceutical products in the biotech market in particular, as well as leading pipeline agents. Includes forecasting, SWOT analysis, R&D assessments, qualitative evaluations.
Pharmacoeconomics and health outcomes research are playing an increasingly important role in informing clinical development and market access decisions of new innovative medicines. Both disciplines are dealing with the evaluation of the costs and outcomes of healthcare interventions and can be considered as two branches of the same “value for money” tree. (Source: Frontiers Reviews, Dominique J. Dubose)
Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region. (Source: Bong-min Yang, PhD, and Kenneth Lee, PhD, Values in Health, Vol. 12, 2009)
Based on data from the Community Tracking Study, the authors found that MCOs were becoming less restrictive over time in terms of limiting provider services, and were more like non-managed care organizations. (Source: International Journal of Health Care Finance and Economics, March 2010)
This paper uses sequential stochastic dominance procedures to compare the joint distribution of health and income across space and time. It is the first application of which we are aware of methods to compare multidimensional distributions of income and health using procedures that are robust to aggregation techniques. The paper's approach is more general than comparisons of health gradients and does not require the estimation of health equivalent incomes.(Source:ScienceDirect Journal, Author:Jean-Yves Duclos, Damien Échevin, Pages 293-302)
Reports showcase expected workforce health conditions (treated and untreated), health status, absence, lost time from presenteeism (health-related inability to function at full capacity while at work), lost productivity and ultimate business impact from various disease states or medical/business scenarios.
in Britain with a £20bn black hole opening up in NHS budgets, a group of top performing trusts are seeking to profit from paying patients and use the money to fund public healthcare in Britain.
U.S. health care costs will increase between 10.5% and 11% over the next year, marginally higher than the increases that occurred during the past two years, but lower than cost increases earlier in the decade, consulting firm Aon (AON) said (Source: Daily Finance, Danny King).
As the politics of the US continues to grind on around providing all Americans with the basics of health care, the government of Singapore has put together a panel of some of the world’s top designers to reshape it’s already terrific medical system so that it attracts people from all over the world to its facilities—and makes high value medicine a 21st century industry. (Source: Bruce Nussbaum, Busienss Week, November 22, 2009)
Sixty-six percent of surveyed respondents across all life science sectors reported having higher spending levels, while 27% expected spending to stay the same, and only seven percent reported a decrease. (Source: Cutting Edge Information, 8/5/2010)
Developed from the rich insights of experienced managers and in-the-field liaisons, this study’s data — including team structures and staffing levels, core HOL activities, compensation benchmarks and profiles of groups in the US, EU and emerging markets — will help you optimize your HOL team.
Erin Hoefligner, of Anthem Blue Cross / Blue Sheild -- Ohio, presents the case that insurance profits are slim and insurers should not be the target for reductions to national health care spending. (Source: Erin Hoeflinger, Cincinnati.com, Nov. 22, 2009)
By Marcial Velasco Garrido, Finn Børlum Kristensen, Camilla
The following papers from the Value in Health Special Issue, Health Technology Assessment in Evidence-Based Health Care Reimbursement Decisions Around the World: Lessons Learned [Volume 12 Issue s2, Pages S1 - S53 (June 2009)] were developed to inform the ongoing debate on the nature and role of HTA. Leading academicians and practitioners from around the world offer their perspectives on HTA in their country and identify lessons learned.
Health, United States, 2009 (with special emphasis on Medical Technology) is the 33rd report on the health status of the United States, prepared by Dept. HHS. The 2009 Chartbook includes 36 charts, with 14 charts illustrating medical technology. There are also 150 trend tables organized around four major subject areas: health status and determinants, health care utilization, health care resources, and health care expenditures. Disability and income/education data are included.
Premier advisory service for executives seeking high-quality strategic information on the business of healthcare. This information hub draws from more than 50 exclusive publications covering five key areas: managed care; hospital and health system management; health law and regulation; clinical care and outcomes; and the healthcare industry.
Authors advocate $US 50,000 per QALY benchmark for determining value for money should be updated, and must vary across payers, populations and even procedures. (Source: PharmacoEconomics: 1 March 2010 - Volume 28 - Issue 3 - pp 175-184)
Healthcare spending should be viewed as an investment in future capital, contributing to a productive workforce, rather than merely as expenditure (published 2011)
HHS State Report includes statistics on health care cost and quality for each of the 50 states in US. Examples include % increase in health premiums, costs of care for uninsured, % of state residents without health insurance, and quality ratings.
In his Policy Address delivered recently, the Chief Executive has proposed to promote the development of Chinese medicine and facilitate its development by introducing new certification services, making Hong Kong a stage for promoting Chinese medicine to the world. (Source: Webnewswire, Nov. 18, 2009)
View and print reports based on your specific requirements. With HospitalBenchmarks.com you have the ability to search on hospital name, hospital provider number, state, city, zip code, or a combination of any of these terms
Differences in what regulators and payers are looking for in post-approval information in Europe and the United States seem to be driving greater regional variations in the types of Phase IV clinical trials that pharmaceutical and biotech companies emphasize.
Bruce Goodman of Humana forecasts the impact of ICD-10, real-time claim adjudication, and role of health insurers in health reform. (Source: WSJ, Nov. 16, 2009)
Your complimentary copy from Xcenda delivers analysis of the major principles underpinning healthcare reform and how its implementation will impact patients’ access to affordable, quality cancer treatment.
Media representatives and other industry stakeholders can access current and historical top-line U.S. and global pharmaceutical trends for use in story development or vital health research initiatives. We provide access to information about leading companies, as well as trends covering products, therapeutic classes, and channels of distribution as measured by prescription sales and dispensing.
The Series, available online or in print, provides key benchmarking data that can help you assess value, control costs, and develop business strategies.
Join thought leaders in the managed care industry to hear different perspectives of the challenges ahead in the 90-minute audio conference, “Forecast: What’s Ahead for Managed Care.”
As healthcare costs rise around the world, executives interviewed for the new study said drug research companies must be ready to provide much more finely detailed patient outcomes data to prove the value of their products.
Learn the current trends in M&A’s, what are the issues, what are state officials' issues, what acquirers are seeking in a suitable fit, the strategic buyer's interests, and, finally, the impact on providers in a consolidated market.
Article examining whether consumers view follow-on and pioneer drugs as close substitutes or distinct clinical therapies. (Source: Forum for Health Economics & Policy 2009)
IBI, Integrated Benefits Institute, surveyed 450 employers to detail the prevalence of health and productivity management (HPM) efforts and interventions, employers' plans over the next two years, goals for these programs, the measurements used to assess key program outcomes and their view of how well HPM initiatives are meeting their desired goals.
Patients in the United States are more likely to forgo medical care because of cost than residents of other developed countries, a new international survey finds. Compared with 10 other industrialized countries, the United States also has the highest out-of-pocket costs and the most complex health insurance, the authors say. (Source: HealthDay, Author: Steven Reinberg)
The Zitter Group’s new Managed Care Oncology Index focuses on both payers and oncology practices, making it the most comprehensive and up-to-date analysis of the major trends underway in the evolving payer market for oncology. This unique study offers pharmaceutical marketers insight into trends in physician reimbursement, product selection, practice profitability, patient access, and how managed care organizations plan to pursue oncology cost-cutting.
Experts from PAREXEL International Corporation will address key trends in health economics and outcomes research techniques, as well as the utilization of pharmacoeconomic studies, cost effective study management, and regulatory risk management requirements.
Among the report's six predicted trends, PwC suggests the government's emphasis on health outcomes as a basis for payments will require pharmaceutical companies to combine product offerings with data and supplemental services that add value through improved outcomes and efficiencies. (Source: ASCReview)
Personalize medicine, which targets individualized treatment and care based on personal and genetic variation, is creating a booming market, but it is a disruptive innovation that PricewaterhouseCoopers says will create both opportunities and challenges for traditional healthcare and emerging market participants. (Source: PR Newswire, New York, Dec. 8, 2009)
Price Waterhouse releases latest report, explaining the need for collaboration with multiple inside and outside parties in order to succeed. Also can download prior Pharma 2020 reports on "The Vision", "Virtual R&D", "Marketing to the Future".
Experts suggest innovate, collaborate, or merge.
Aside from defending against generic competition, lifecycle management strategies enable companies to sustain their revenue streams and fill gaps in their pipelines as increasing numbers of key brands begin to lose patent protection.
More than three years have passed since IMS Health first coined the term “pharmerging market” in recognition of the major shift in growth away from the mature, developed economies to the seven fast-growing emerging economies of China, Brazil, Russia, India, Mexico,Turkey, and South Korea. (Source: IMS Market Prognosis, 2006-2010)
Trends and forecasting report on the status of the pharma industry for the next decade.
Ponemon Institute published their study surveying American opinions on privacy of their health information. They found: 71% of Americans trust their providers with their medical information much more than they trust payers (43%), state and local government (31%), private information technology companies (27%) or the federal government (27%). (Source: Health Care Technology News, Feb. 1, 2010)
Pharmaceutical companies' efforts to promote prescription drugs have attracted the attention of policymakers because such activities may affect the rate at which different drugs are prescribed and consumed, the total amount spent on health care, and, ultimately, health outcomes. (Source: Sheila Campbell, CBO - Economic and Budget Issue Breif, Dec. 2, 2009)
This 50-page special report contains insider information from three leading experts in DM analytics. They review key principles in calculating ROI, how to establish metrics for evaluating DM programs, and common mistakes in measuring ROI. They also share some relevant case studies for comparison.There is a fee to order this report.
The statement's provocative recommendations include the imposition of requirements that (a) the off-label drug should be "irreplaceable for treatment of the patient," that is, no drug labeled for the indication is available; (b) the off-label use must be "submitted and approved by the hospital's pharmacotherapy committee and hospital ethics committee" except in emergency situations; and (c) informed consent for off-label use must be obtained from the patient or a legal representative.
(Source: JMCP October 2010 Volume 16 Issue 8, Authors: Kathleen A. Fairman, MA, and Frederic R. Curtiss, PhD, RPh, CEBS)
The strong correlation between infectious diseases and cancer has additionally fueled the incidence rates of various cancers, driving the pharmaceutical industry in key east African countries.
Romanian Pharmaceutical Market 2011, Annual Review
Pricing and reimbursement arrangements for prescription medicines are summarized. Spending by Spain’s National Health Service (NHS) on pharmaceuticals was €12.1 billion in 2010.(Source: OHE News)
Although many have brought attention to this field's increasing importance in medical education, surprisingly little is known about how exactly health policy is taught in medical schools. (Source:NEJM, 2/23/2011, Mou, David, et.al.)
The Medical Device Daily-State of the Industry Report 2011 is our all-inclusive report of the entire year – it’s the executive summary that is relied on year after year by executives for their business intelligence and historical overview of the issues and events impacting the med-tech industry.
Excellent report containing great metrics and trends on health care costs
A new study funded by the National Pharmaceutical Council (NPC) shows that pharmacogenomics -- the field of scientific research focused on learning how genetic profiles predict the body's response to medicines - has the potential to lead to higher levels of research and development (R&D) investment and an increased pace of pharmaceutical innovation, offering substantial benefits for patients. (Source: PharmacoEconomics, Volume 27, Number 5, 5 May 2009 , pp. 355-363(9))
The report addresses use of HTA in establishing health care policy in Asia.
by Brian Smith (pharma industry exec and editor of Jnl of Medical Marketing). Brian Smith's highly readable research findings are a wake up call and a first-step forward for anyone concerned with the future of the industry; whether executive, customer, policymaker or investor
The Indian pharma market has witnessed a successful growth rate of 21.3 per cent for the 12 months ending September 2010 . However, it is not just a growth story as the $12.6 billion Indian pharma market is currently the world's second largest by volume.
HHS State Report has recently been issued, including statistics on health care cost and quality for each of the 50 states in US. Examples include % increase in health premiums, costs of care for uninsured, % of state residents without health insurance, and quality ratings.
The market structure of the U. S. health industry not only reflects the nature of health care, but also its origins in the 1930's and its evolution in succeeding decades. This report discusses how the current health insurance market structure affects the two policy goals of expanding insurance coverage and containing health care costs. (Source: D. Andrew Austin and Thomas L. Hungerford, weSRCH, Nov. 17, 2009)
Remember the 4-P's of Marketing (product, placement, price, and promotion)? PharmExec.Com suggests these have been replaced by 4 New P's: Predictive Modeling, Personalization, Peer-to-Peer, Participation.
Management report that assesses the impact that pharmacoeconomics has had on the pharmaceutical industry and shows how companies can utilize pharmacoeconomic modeling to gain a competitive edge. This report examines the most commonly used pharmacoeconomic methodologies with respect to both study perspective and the range of R&D costs that can be analyzed.
This Statistical Brief discusses both changes in health insurance offers by private sector employers and changes in enrollment by their employees from 1998 to 2008. (Source: AHRQ.gov, Oct 2009)
A November 2010 report from the International Federation of Health Plans (iFHP) highlighted differences in health care prices across different countries. It is no surprise that the U.S. leads the world in costs and prices for the 14 different services and procedures, which ranged from hip replacements to MRIs. The real concern, of course, is that our health outcomes are not better, and in fact, worse than many of the other countries that spend far less than the U.S. does on health care.(Source: RX Outcomes Advisor)
Report from House of Parliament.
Despite having the highest incomes, people in Britain have the worst quality of life in Europe, a study shows. (Source: PressTV, October 2009)
Market Report: Ukraine Pharmaceuticals and Healthcare Report Q4 2009 (Source: Business Monitor International, Oct 2009)
The number of drugs entering the US pharmaceutical market is at a low point. At the same time, demand for innovative therapeutic alternatives has been rising in numerous fields, including antibiotics for multidrug resistant organisms and drugs for tropical diseases prevalent in low-income settings. The growing gap between the need for new pharmaceuticals and their development and approval for use in clinical care has drawn the attention of policymakers from diverse sources, including academia, industry, and government. (Source:NEJM 2010, Vol. 363, No. 19, pp. 1855-1862)
Interview covering trends and major challenges in HEOR.
The new value-based pricing strategy will radically overhaul the way medicines are paid for. Once the PPRS scheme has run its course by 2014, grug prices will be set according to the value the medicines provide. The White Paper also proposes changes to the role of NICE (National Institute of Clinical Excellence) and structural shifts in the way that budgets are managed – with 80% of control being handed over to GP’s. (Source: InPharm.)
WellPoint Institute of Health Care Knowledge releases report detailing the primary drivers of increased health care services and health insurance premiums, dispelling the notion that insurer profits are fueling spiking costs.
Learn from the pioneers how to use self-reporting tools. Nine case studies apply to a variety of employers and tools.
